The Doxorubicin Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
According to The Business Research Company’s Doxorubicin Global Market Report 2024, The doxorubicin market size has grown strongly in recent years. It will grow from .23 billion in 2023 to .32 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to chemotherapy advancements, oncology treatment standard, clinical efficacy, patient survival rates, physician recommendations.
The doxorubicin market size is expected to see strong growth in the next few years. It will grow to .71 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to personalized medicine advancements, targeted drug delivery systems, immunotherapy combinations, genomic and biomarker research, precision oncology growth. Major trends in the forecast period include nanotechnology integration, combination therapies, biosimilar market expansion, adjuvant therapy focus, cardioprotective interventions.
The increasing prevalence of cancer is driving the doxorubicin market forward. Cancer is a group of diseases in which cells grow abnormally and uncontrollably. Doxorubicin is a common antibiotic used in chemotherapy to treat distinct types of cancers, as it limits the growth of cancer cells by damaging their DNA. The growing incidence of cancer has led to a higher demand for doxorubicin. For instance, according to the 2021 American Cancer Society report, 1.8 million new cases of cancer diagnosed were diagnosed in 2020. Furthermore, according to September 2020 data published by the National Cancer Institute, a US-based government agency part of the National Institutes of Health, 1,806,590 new cancer cases were recorded, indicating that 43% of all cancer diagnosed in men in the United States in 2020, up from 1,752,735 in the previous year, i.e., 2019. Thus, the increasing prevalence of cancer patients is driving the doxorubicin market.
The doxorubicin market covered in this report is segmented – 1) By Drug Formulation: Lyophilized Powder, Doxorubicin Injection 2) By Application: Breast Cancer, Kidney Cancer, Liver Cancer, Sarcoma, Ovarian Cancer, Lung Cancer, Leukemia, Multiple Myeloma, Other Applications 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Advancements in drug Investigation are a key trend gaining popularity in the doxorubicin market. Major companies in the doxorubicin market are working on innovative technologies to launch advanced products, such as injections, to sustain their position in the market. For instance, in October 2021, Padagis, a US-based healthcare company, received approval for its AB-rated generic version of Doxil (Doxorubicin Liposome Injection) from the US Food and Drug Administration, a US-based health regulatory agency. The new drug is an anthracycline topoisomerase inhibitor used for treating ovarian cancer, sarcoma, and multiple myeloma. It is also used in the treatment of multiple myeloma alongside bortezomib. Doxorubicin liposome is a cancer medication that acts as an antineoplastic agent.
The doxorubicin market report table of contents includes: 1. Executive Summary 2. Doxorubicin Market Characteristics 3. Doxorubicin Market Trends And Strategies 4. Doxorubicin Market - Macro Economic Scenario 5. Global Doxorubicin Market Size and Growth .... 31. Global Doxorubicin Market Competitive Benchmarking 32. Global Doxorubicin Market Competitive Dashboard 33. Key Mergers And Acquisitions In The Doxorubicin Market 34. Doxorubicin Market Future Outlook and Potential Analysis 35. Appendix
Contact Us: The Business Research Company Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293 Email: info@tbrc.info
Like it? Share it!
About the Author
Ramakrishna TBRC Joined: December 17th, 2019 Articles Posted: 623
